<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175808</url>
  </required_header>
  <id_info>
    <org_study_id>20090231</org_study_id>
    <secondary_id>2018-003157-19</secondary_id>
    <nct_id>NCT04175808</nct_id>
  </id_info>
  <brief_title>Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Subjects</brief_title>
  <official_title>Single-dose and Randomized, Single-center, Placebo- and Active-controlled, Crossover Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of a single therapeutic (50 mg) oral dose of OM on the QT/QT interval
      corrected for heart rate (QTc) interval, relative to placebo, in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2019</start_date>
  <completion_date type="Actual">March 4, 2020</completion_date>
  <primary_completion_date type="Actual">March 4, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in QT interval corrected for heart rate based on the Fridericia correction</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>The placebo-corrected after Omecamtiv mecarbil (OM) dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters for Omecamtiv mecarbil following oral administration included but not limited to maximum serum concentration (Cmax)</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of Omecamtiv mecarbil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for Omecamtiv mecarbil following oral administration included but not limited to time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of Omecamtiv mecarbil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for Omecamtiv mecarbil following oral administration included but not limited to if feasible, half-life (t1/2)</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of Omecamtiv mecarbil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for Omecamtiv mecarbil following oral administration included but not limited apparent volume of distribution (VZ/F)</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of Omecamtiv mecarbil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for Omecamtiv mecarbil following oral administration included but not limited apparent total plasma clearance (CL/F)</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of Omecamtiv mecarbil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for Omecamtiv mecarbil following oral administration included but not limited area under the concentration-time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t)</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of Omecamtiv mecarbil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for Omecamtiv mecarbil following oral administration included but not limited AUC from time 0 to infinity (AUCinf)</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of Omecamtiv mecarbil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for Omecamtiv mecarbil following oral administration included but not limited the percentage of AUCinf due to extrapolation (%AUCextrap)</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of Omecamtiv mecarbil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in T-wave morphology</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>Frequency of treatment-emergent after OM dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in U-wave presence</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>Frequency of treatment-emergent after OM dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Changes in laboratory safety tests</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To assess the effect of omecamtiv mecarbil in subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Changes in Blood pressure</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To assess the effect of omecamtiv mecarbil in subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Changes in ECGs parameters</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To assess the effect of omecamtiv mecarbil in subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To assess the effect of omecamtiv mecarbil in subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Changes in pulse rate</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To assess the effect of omecamtiv mecarbil in subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Changes in body temperature</measure>
    <time_frame>Day-1 to Day-6</time_frame>
    <description>To assess the effect of omecamtiv mecarbil in subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>QT Intervals Changes</condition>
  <condition>QTc Intervals Changes</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 1 omecamtiv mecarbil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 treatments in 1 of 6 sequences</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omecamtiv Mecarbil (OM)</intervention_name>
    <description>In Part A treatment 1: 25-mg OM oral solution. In Part B treatment B: 50-mg OM oral solution</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment A: Placebo oral solution</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Treatment C: 400-mg moxifloxacin oral tablet</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has provided informed consent before initiation of any study-specific
             activities/procedures.

          -  Healthy male or healthy female subjects greater than or equal to 18 to less than or
             equal to 50 years of age.

          -  No history or evidence of clinically relevant medical disorders as determined by the
             Investigator at Screening.

          -  Physical examination at Screening and vital signs, clinical laboratory values, and
             ECGs at Screening and Day -1 of each period are clinically acceptable to the
             Investigator.

          -  Body mass index (BMI) greater than, equal to 18.0 kg/m2 and less than, or equal to
             30.0 kg /m2.

          -  Willing to maintain current general diet and physical activity regimen.

        Exclusion Criteria:

          -  History or evidence of clinically significant disorder, condition, or disease not
             otherwise excluded that, in the opinion of the Investigator, would pose a risk to
             subject safety or interfere with the study evaluation, procedures, or completion.

          -  Any users of tobacco- or nicotine-containing products within 6 months before Day -1 of
             Part A.

          -  History suggestive of esophageal (including esophageal spasm, esophagitis), gastric,
             or duodenal ulceration or bowel disease (including, but not limited to, peptic
             ulceration, gastrointestinal bleeding, ulcerative colitis, Crohn's disease, or
             irritable bowel syndrome); or a history of gastrointestinal surgery other than
             uncomplicated appendectomy.

          -  History or current signs or symptoms of cardiovascular disease, including but not
             limited to myocardial infarction, congenital heart disease, valvular heart disease,
             coronary revascularization, or angina.

          -  Known substance abuse (eg, alcohol, licit or illicit drugs) within 1 year prior to
             Screening.

          -  Subjects with poor peripheral venous access.

          -  Use of any medications/substances outside the allowed timeframes as specified in
             Section 6.1.2.

          -  Currently receiving treatment in another investigational device or drug study, or less
             than 3 months, or 5 half-lives if longer, prior to receiving the first dose of study
             drug. Other investigational procedures while participating in this study are excluded.

          -  Donated blood from 3 months prior to Screening, plasma from 2 weeks prior to
             Screening, or platelets from 6 weeks prior to Screening.

          -  Subjects who were previously exposed to OM.

          -  Hepatic impairment defined by a total bilirubin (TBL) greater than or equal to 1.2
             times the upper limit of normal (ULN), or alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) greater than ULN (and confirmed upon repeat).

          -  Systolic blood pressure (BP) grater than 140 mmHg or less than 90 mmHg, or diastolic
             BP greater than 90 mmHg.

          -  QTcF interval greater than 450 msec in male or greater than 470 msec in female or
             history/evidence of long QT syndrome, or PR of greater than or equal to 200 msec; or
             2nd degree atrioventricular (AV) block or 3rd degree AV block, or heart rate greater
             than 100 bpm (and confirmed upon repeat, except 2nd or 3rd degree AV block, which are
             exclusionary based on a single finding).

          -  Troponin I or creatine kinase MB fraction (CK-MB) greater than ULN at Screening or
             Check-in for Part A or B.

          -  Estimated glomerular filtration rate (eGFR) less than 80 mL/min/1.73 m2 at Screening
             as calculated by the Modified Diet in Renal Disease (MDRD) equation;

          -  Any positive test for drugs, cotinine (tobacco or nicotine use), and/or alcohol use.

          -  Positive hepatitis panel and/or positive human immunodeficiency virus test. Subjects
             whose results are compatible with prior immunization may be included.

          -  Subject has known sensitivity to any of the products or components to be administered
             during dosing, including history of hypersensitivity to moxifloxacin or any member of
             the quinolone class of antibacterials.

          -  History of tendon rupture or connective tissue disorders.

          -  Female subjects with a positive pregnancy test.

          -  Female subjects lactating/breastfeeding or who plans to breastfeed during the study
             through 90 days after the EOS visit.

          -  Unwilling to adhere to contraceptive requirements through 90 days after the EOS visit
             (see Appendix 7).

          -  Unwilling to abstain from sperm and ovum donation through 90 days after the EOS visit.

          -  Male subjects with a female partner of childbearing potential and not willing to
             inform his partner of his participation in this clinical study.

          -  Male subjects with a pregnant partner or partner planning to become pregnant while the
             subject is on study through 90 days after the EOS visit.

          -  Subject likely to not be available to complete all protocol-required study visits or
             procedures, and/or to comply with all required study procedures (eg, Clinical Outcome
             Assessments) to the best of the subject and Investigator's knowledge.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thorough QT</keyword>
  <keyword>QTc study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

